- Home
- STTK vs FSI Comparison
STTK vs FSI Comparison
Compare STTK & FSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- FSI
- Stock Information
- Founded
- STTK 2016
- FSI 1991
- Country
- STTK United States
- FSI Canada
- Employees
- STTK N/A
- FSI N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- FSI Recreational Games/Products/Toys
- Sector
- STTK Health Care
- FSI Consumer Discretionary
- Exchange
- STTK Nasdaq
- FSI Nasdaq
- Market Cap
- STTK 56.8M
- FSI 47.3M
- IPO Year
- STTK 2020
- FSI 1999
- Fundamental
- Price
- STTK $1.23
- FSI $6.13
- Analyst Decision
- STTK Hold
- FSI
- Analyst Count
- STTK 3
- FSI 0
- Target Price
- STTK $2.00
- FSI N/A
- AVG Volume (30 Days)
- STTK 127.4K
- FSI 1.1M
- Earning Date
- STTK 02-27-2025
- FSI 03-31-2025
- Dividend Yield
- STTK N/A
- FSI 1.61%
- EPS Growth
- STTK N/A
- FSI 11.03
- EPS
- STTK N/A
- FSI 0.33
- Revenue
- STTK $6,435,000.00
- FSI $38,493,925.00
- Revenue This Year
- STTK $313.04
- FSI $0.73
- Revenue Next Year
- STTK N/A
- FSI $34.59
- P/E Ratio
- STTK N/A
- FSI $18.82
- Revenue Growth
- STTK 382.75
- FSI N/A
- 52 Week Low
- STTK $0.94
- FSI $1.65
- 52 Week High
- STTK $11.76
- FSI $6.75
- Technical
- Relative Strength Index (RSI)
- STTK 52.10
- FSI 64.67
- Support Level
- STTK $1.11
- FSI $5.90
- Resistance Level
- STTK $1.36
- FSI $6.49
- Average True Range (ATR)
- STTK 0.11
- FSI 0.60
- MACD
- STTK 0.01
- FSI 0.06
- Stochastic Oscillator
- STTK 56.67
- FSI 77.54
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About FSI Flexible Solutions International Inc. (CDA)
Flexible Solutions International Inc develops, manufactures, and markets specialty chemicals that slow the evaporation of water. Its business is organized into two segments Energy and Water Conservation Products, and Biodegradable Polymers. It offers a liquid swimming pool blanket under the WATERSAVR brand, which saves energy and water by inhibiting evaporation from the pool surface, a chemical product called HEATSAVR, for use in swimming pools and spas to slow the water evaporation. The firm also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers. It generates most of its revenues from the export of its products to international markets.